173 related articles for article (PubMed ID: 38050202)
41. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
[TBL] [Abstract][Full Text] [Related]
42. ctDNA as a prognostic factor in operable colon cancer patients: a systematic review and meta-analysis.
Yekedüz E; Köksoy EB; Akbulut H; Ürün Y; Utkan G
Future Oncol; 2021 Jan; 17(3):349-357. PubMed ID: 33356539
[No Abstract] [Full Text] [Related]
43. Circulating tumor cells (CTCs) detected by RT-PCR and its prognostic role in gastric cancer: a meta-analysis of published literature.
Wang S; Zheng G; Cheng B; Chen F; Wang Z; Chen Y; Wang Y; Xiong B
PLoS One; 2014; 9(6):e99259. PubMed ID: 24901848
[TBL] [Abstract][Full Text] [Related]
44. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer.
Chen G; Peng J; Xiao Q; Wu HX; Wu X; Wang F; Li L; Ding P; Zhao Q; Li Y; Wang D; Shao Y; Bao H; Pan Z; Ding KF; Cai S; Wang F; Xu RH
J Hematol Oncol; 2021 May; 14(1):80. PubMed ID: 34001194
[TBL] [Abstract][Full Text] [Related]
45. Preoperative serum ctDNA predicts early hepatocellular carcinoma recurrence and response to systemic therapies.
Fu Y; Yang Z; Hu Z; Yang Z; Pan Y; Chen J; Wang J; Hu D; Zhou Z; Xu L; Chen M; Zhang Y
Hepatol Int; 2022 Aug; 16(4):868-878. PubMed ID: 35674872
[TBL] [Abstract][Full Text] [Related]
46. Association of ctDNA detection and recurrence assessment in patients with neoadjuvant treatment.
Zhou J; Mo H; Hu D; Zhao X; Zhou H; Pan J
Cancer Med; 2023 Oct; 12(19):19794-19806. PubMed ID: 37746916
[TBL] [Abstract][Full Text] [Related]
47. Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study.
Øgaard N; Reinert T; Henriksen TV; Frydendahl A; Aagaard E; Ørntoft MW; Larsen MØ; Knudsen AR; Mortensen FV; Andersen CL
Eur J Cancer; 2022 Mar; 163():163-176. PubMed ID: 35074652
[TBL] [Abstract][Full Text] [Related]
48. The role of liquid biopsy in predicting post-operative recurrence of non-small cell lung cancer.
Liang H; Huang J; Wang B; Liu Z; He J; Liang W
J Thorac Dis; 2018 Apr; 10(Suppl 7):S838-S845. PubMed ID: 29780630
[TBL] [Abstract][Full Text] [Related]
49. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study.
Schraa SJ; van Rooijen KL; van der Kruijssen DEW; Rubio Alarcón C; Phallen J; Sausen M; Simmons J; Coupé VMH; van Grevenstein WMU; Elias S; Verkooijen HM; Laclé MM; Bosch LJW; van den Broek D; Meijer GA; Velculescu VE; Fijneman RJA; Vink GR; Koopman M;
BMC Cancer; 2020 Aug; 20(1):790. PubMed ID: 32819390
[TBL] [Abstract][Full Text] [Related]
50. A meta-analysis of circulating tumor DNA as a survival indicator in small cell lung cancer patients.
Li J; Wang L; Dong Z; Song Q; Wang Z
Clin Exp Med; 2023 Nov; 23(7):3935-3945. PubMed ID: 37027065
[TBL] [Abstract][Full Text] [Related]
51. Prognostic Value of Circulating Tumour DNA in Asian Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Liu H; Yang H; Chen X
Evid Based Complement Alternat Med; 2022; 2022():8019652. PubMed ID: 35251214
[TBL] [Abstract][Full Text] [Related]
52. Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers.
Huffman BM; Aushev VN; Budde GL; Chao J; Dayyani F; Hanna D; Botta GP; Catenacci DVT; Maron SB; Krinshpun S; Sharma S; George GV; Malhotra M; Jurdi A; Moshkevich S; Aleshin A; Kasi PM; Klempner SJ
JCO Precis Oncol; 2022 Dec; 6():e2200420. PubMed ID: 36480779
[TBL] [Abstract][Full Text] [Related]
53. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.
Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH
Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868
[No Abstract] [Full Text] [Related]
54. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.
Powles T; Assaf ZJ; Davarpanah N; Banchereau R; Szabados BE; Yuen KC; Grivas P; Hussain M; Oudard S; Gschwend JE; Albers P; Castellano D; Nishiyama H; Daneshmand S; Sharma S; Zimmermann BG; Sethi H; Aleshin A; Perdicchio M; Zhang J; Shames DS; Degaonkar V; Shen X; Carter C; Bais C; Bellmunt J; Mariathasan S
Nature; 2021 Jul; 595(7867):432-437. PubMed ID: 34135506
[TBL] [Abstract][Full Text] [Related]
55. Effect of Chemoradiotherapy on the Survival of Resectable Gastric Cancer Patients: A Systematic Review and Meta-Analysis.
Lu H; Sun Y; Zhu Z; Yao J; Xu H; Huang R; Huang B
Ann Surg Oncol; 2022 Oct; 29(11):6962-6975. PubMed ID: 35723792
[TBL] [Abstract][Full Text] [Related]
56. Development and validation of postoperative circulating tumor DNA combined with clinicopathological risk factors for recurrence prediction in patients with stage I-III colorectal cancer.
Gao Z; Huang D; Chen H; Yang Y; An K; Ding C; Yuan Z; Zhai Z; Niu P; Gao Q; Cai J; Zeng Q; Wang Y; Hong Y; Rong W; Huang W; Lei F; Wang X; Chen S; Zhao X; Bai Y; Gu J
J Transl Med; 2023 Jan; 21(1):63. PubMed ID: 36717891
[TBL] [Abstract][Full Text] [Related]
57. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Tomita Y; Moldovan M; Chang Lee R; Hsieh AH; Townsend A; Price T
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD012078. PubMed ID: 33210731
[TBL] [Abstract][Full Text] [Related]
58. Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA.
Benešová L; Hálková T; Ptáčková R; Semyakina A; Menclová K; Pudil J; Ryska M; Levý M; Šimša J; Pazdírek F; Hoch J; Blaha M; Minárik M
World J Gastroenterol; 2019 Dec; 25(48):6939-6948. PubMed ID: 31908397
[TBL] [Abstract][Full Text] [Related]
59. Liquid biopsy: circulating tumor DNA monitors neoadjuvant chemotherapy response and prognosis in stage II/III gastric cancer.
Zhang M; Yang H; Fu T; Meng M; Feng Y; Qu C; Li Z; Xing X; Li W; Ye M; Li S; Bu Z; Jia S
Mol Oncol; 2023 Sep; 17(9):1930-1942. PubMed ID: 37356061
[TBL] [Abstract][Full Text] [Related]
60. Prognostic potential of circulating tumor DNA detection at different time periods in resectable non-small cell lung cancer: Evidence from a meta-analysis.
Wang B; Pei J; Wang S; Cheng K; Yu J; Liu J
Crit Rev Oncol Hematol; 2022 Sep; 177():103771. PubMed ID: 35905822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
